Abstract
The methylhydrazine derivative Procarbazine (PCZ) as monotherapy or in combination with CCNU and vincristine (PCV) was evaluated in a vast number of clinical trials and is still used in patients with high-grade and low-grade gliomas. The compound is an antineoplastic agent with multiple sites of action. It inhibits incorporation of small DNA precursors, as well as RNA and protein synthesis. PCZ can also directly damage DNA through an alkylation reaction. The drug is not cross-resistant with other mustard-type alkylating agents. As PCZ was in almost all trials used in a combination with CCNU and Vincristin, the efficacy can only be evaluated in the view of the PCV regimen. The published data suggest a role of PCV as a salvage regimen, especially in oligodendroglial tumors; however, well designed studies with high evidence are rare in all entities. This article summarizes the existing data with the goal to define the role of PCZ/PCV in modern neurooncology.
Keywords: Procarbazine, PCV, pharmacokinetics, chemotherapy, glioma, glioblastoma, anaplastic glioma, clinical trial
Current Medicinal Chemistry
Title: Procarbazine – A Traditional Drug in the Treatment of Malignant Gliomas
Volume: 15 Issue: 14
Author(s): Rainer Goerne, Ulrich Bogdahn and Peter Hau
Affiliation:
Keywords: Procarbazine, PCV, pharmacokinetics, chemotherapy, glioma, glioblastoma, anaplastic glioma, clinical trial
Abstract: The methylhydrazine derivative Procarbazine (PCZ) as monotherapy or in combination with CCNU and vincristine (PCV) was evaluated in a vast number of clinical trials and is still used in patients with high-grade and low-grade gliomas. The compound is an antineoplastic agent with multiple sites of action. It inhibits incorporation of small DNA precursors, as well as RNA and protein synthesis. PCZ can also directly damage DNA through an alkylation reaction. The drug is not cross-resistant with other mustard-type alkylating agents. As PCZ was in almost all trials used in a combination with CCNU and Vincristin, the efficacy can only be evaluated in the view of the PCV regimen. The published data suggest a role of PCV as a salvage regimen, especially in oligodendroglial tumors; however, well designed studies with high evidence are rare in all entities. This article summarizes the existing data with the goal to define the role of PCZ/PCV in modern neurooncology.
Export Options
About this article
Cite this article as:
Goerne Rainer, Bogdahn Ulrich and Hau Peter, Procarbazine – A Traditional Drug in the Treatment of Malignant Gliomas, Current Medicinal Chemistry 2008; 15 (14) . https://dx.doi.org/10.2174/092986708784567707
DOI https://dx.doi.org/10.2174/092986708784567707 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Contrasting Roles of NKT Cells in Tumor Immunity
Current Molecular Medicine Major Developments in the Design of Inhibitors along the Kynurenine Pathway
Current Medicinal Chemistry Melatonin and Synthetic Melatoninergic Agonists in Psychiatric and Age-associated Disorders: Successful and Unsuccessful Approaches
Current Pharmaceutical Design Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer
Current Topics in Medicinal Chemistry Improving the Hsp90 Inhibitors Containing 4-(2,4-Dihydroxyphenyl)-1,2,3-thiadiazole Scaffold: Synthesis, Affinity and Effect on Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Molecular Imaging of Breast Cancer: Role of RGD Peptides
Mini-Reviews in Medicinal Chemistry Current State of the Art of New Tubulin Inhibitors in the Clinic
Current Clinical Pharmacology A Concise Review of Current Radiopharmaceuticals in Tumor Angiogenesis Imaging
Current Pharmaceutical Design Thalidomide Derived Immunomodulatory Drugs (IMiDs) as Potential Therapeutic Agents
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Convection Enhanced Drug Delivery of Novel Therapeutic Agents to Malignant Brain Tumors
Current Drug Delivery Molecular Imaging of Brain Tumors Personal Experience and Review of the Literature
Current Molecular Medicine Nanotechnology in Neuroscience and its Perspective as Gene Carrier
Current Topics in Medicinal Chemistry Protein/ Hormone Based Nanoparticles as Carriers for Drugs Targeting Protein-Protein Interactions
Current Topics in Medicinal Chemistry Editorial [Hot Topic: Targeted Therapies in Oncology (Guest Editor: Monica M. Mita)]
Current Drug Targets Current and Future Drug Treatments for Glioblastomas
Current Medicinal Chemistry Mesenchymal Stem Cells: An Emerging Tool for Cancer Targeting and Therapy
Current Stem Cell Research & Therapy Thioredoxin, Glutathione and Related Molecules in Tumors of the Nervous System
Current Medicinal Chemistry Diffusion-Weighted MRI for Assessment of Early Cancer Treatment Response
Current Pharmaceutical Biotechnology Pro-Oxidant Milieu Blunts Scissors: Insight into Tumor Progression, Drug Resistance, and Novel Druggable Targets
Current Pharmaceutical Design Molecular Chaperone ORP150 in ER Stress–related Diseases
Current Pharmaceutical Design